Literature DB >> 6652975

The primary immune response in patients with selective IgA deficiency.

P A De Graeff, T H The, P J van Munster, T A Out, J M Vossen, B J Zegers.   

Abstract

The primary immune response in vivo of 20 patients with selective IgA deficiency was studied and compared to controls. The primary cellular immune response tested by dinitrochlorobenzene (DNCB) was decreased in many patients. The primary humoral immune response was elicited by immunization with the test immunogen Helix pomatia haemocyanin (HPH). Using a direct ELISA technique antibodies against HPH of the IgA, IgG and IgM class were measured. Two weeks after immunization no response of IgA anti-HPH was seen except in three patients who showed a low but detectable antibody level. In spite of normal or even elevated serum IgG and IgM levels there was a significantly lower response of the IgG and IgM anti-HPH antibodies at 2 weeks after immunization as compared to the controls followed by a further decline at 6 weeks. We conclude that selective IgA deficiency is often accompanied by more general disturbances in humoral and cellular immunity to newly encountered antigens.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6652975      PMCID: PMC1536142     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  15 in total

1.  Defect in IgA secretion and in IgA specific suppressor cells in patients with selective IgA deficiency.

Authors:  T A Waldmann; S Broder; R Krakauer; M Durm; B Meade; C Goldman
Journal:  Trans Assoc Am Physicians       Date:  1976

2.  Serum immunoglobulins in healthy children and adults. Levels of the five classes, expressed in international units per millilitre.

Authors:  B J Zegers; J W Stoop; E E Reerink-Brongers; P C Sander; R C Aalberse; R E Ballieux
Journal:  Clin Chim Acta       Date:  1975-12-15       Impact factor: 3.786

3.  Suppressor cells and IgA deficiency.

Authors:  J S Atwater; T B Tomasi
Journal:  Clin Immunol Immunopathol       Date:  1978-03

4.  Functional assessment of a B cell defect in patients with selective IgA deficiency.

Authors:  J T Cassidy; G Oldham; T A Platts-Mills
Journal:  Clin Exp Immunol       Date:  1979-02       Impact factor: 4.330

5.  The human immune response to alpha-haemocyanin of Helix pomatia.

Authors:  G C de Gast; T H The; J A Snijder
Journal:  Acta Med Scand       Date:  1973-10

6.  Selective IgA deficiency: presentation of 30 cases and a review of the literature.

Authors:  A J Ammann; R Hong
Journal:  Medicine (Baltimore)       Date:  1971-05       Impact factor: 1.889

7.  Cellular aspects of selective IgA deficiency.

Authors:  G Delespesse; P Gausset; C Cauchie; A Govaerts
Journal:  Clin Exp Immunol       Date:  1976-05       Impact factor: 4.330

8.  Estimation of basophil-bound IgE by quantitative immunofluorescence microscopy.

Authors:  P J Stallman; R C Aalberse
Journal:  Int Arch Allergy Appl Immunol       Date:  1977

9.  Class-specific antibody titres (ELISA) against the primary immunogen Helix pomatia haemocyanin (HPH) in man.

Authors:  J Weits; G C de Gast; T H The; M T Esselink; A M Deelder; M Petrovic; E Mandema
Journal:  Clin Exp Immunol       Date:  1978-06       Impact factor: 4.330

10.  Differentiation capacity of cultured B lymphocytes from immunodeficient patients.

Authors:  L Y Wu; A R Lawton; M D Cooper
Journal:  J Clin Invest       Date:  1973-12       Impact factor: 14.808

View more
  10 in total

1.  Defective anti-polysaccharide IgG vaccine responses in IgA deficient mice.

Authors:  Yoichi Furuya; Girish S Kirimanjeswara; Sean Roberts; Rachael Racine; Jennifer Wilson-Welder; Alan M Sanfilippo; Sharon L Salmon; Dennis W Metzger
Journal:  Vaccine       Date:  2017-07-31       Impact factor: 3.641

2.  Immunoglobulin subclass distribution of human anti-carbohydrate antibodies: aberrant pattern in IgA-deficient donors.

Authors:  L Hammarström; M A Persson; C I Smith
Journal:  Immunology       Date:  1985-04       Impact factor: 7.397

3.  Antibody responses in vivo in chromosome instability syndromes with immunodeficiency.

Authors:  C M Weemaes; T H The; P J van Munster; J A Bakkeren
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

4.  Severity of infections in IgA deficiency: correlation with decreased serum antibodies to pneumococcal polysaccharides and decreased serum IgG2 and/or IgG4.

Authors:  M A French; K A Denis; R Dawkins; J B Peter
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

5.  Antibody deficiency and isolated growth hormone deficiency in a girl with Mulibrey nanism.

Authors:  A Haraldsson; C J van der Burgt; C M Weemaes; B Otten; J A Bakkeren; G B Stoelinga
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

6.  An investigation into the effect of the IgG antibody system on the susceptibility of IgA-deficient patients to respiratory tract infections.

Authors:  M A French; G Harrison
Journal:  Clin Exp Immunol       Date:  1986-12       Impact factor: 4.330

7.  Heterogeneity of immune defects in three children with a chronic active Epstein-Barr virus infection.

Authors:  W Kuis; J J Roord; B J Zegers; A B Rickinson; J G Kapsenberg; H The; J W Stoop
Journal:  J Clin Immunol       Date:  1985-11       Impact factor: 8.317

8.  Immunological investigations in individuals with selective IgA deficiency.

Authors:  T A Out; P J van Munster; P A De Graeff; T H Thé; J M Vossen; B J Zegers
Journal:  Clin Exp Immunol       Date:  1986-06       Impact factor: 4.330

Review 9.  The Clinical Utility of Measuring IgG Subclass Immunoglobulins During Immunological Investigation for Suspected Primary Antibody Deficiencies.

Authors:  Antony R Parker; Markus Skold; David B Ramsden; J Gonzalo Ocejo-Vinyals; Marcos López-Hoyos; Stephen Harding
Journal:  Lab Med       Date:  2017-11-08

10.  Immunoglobulin G, A, and M light chain ratios in some humoral immunological disorders.

Authors:  A Haraldsson; M Jaminon; J A Bakkeren; G B Stoelinga; C M Weemaes
Journal:  Scand J Immunol       Date:  1992-07       Impact factor: 3.487

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.